502 related articles for article (PubMed ID: 23818527)
21. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
22. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
23. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
24. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
25. Is there a place for incretin therapies in obesity and prediabetes?
Holst JJ; Deacon CF
Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
Mentlein R
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
Mayer F; Gunawan AL; Tso P; Aponte GW
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
[TBL] [Abstract][Full Text] [Related]
28. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Hirano T; Mori Y
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
[TBL] [Abstract][Full Text] [Related]
29. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
Hinke SA; Manhart S; Kühn-Wache K; Nian C; Demuth HU; Pederson RA; McIntosh CH
J Biol Chem; 2004 Feb; 279(6):3998-4006. PubMed ID: 14610075
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell JE; Drucker DJ
Cell Metab; 2013 Jun; 17(6):819-837. PubMed ID: 23684623
[TBL] [Abstract][Full Text] [Related]
31. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
Hutch CR; Roelofs K; Haller A; Sorrell J; Leix K; D'Alessio DD; Augustin R; Seeley RJ; Klein T; Sandoval DA
Diabetologia; 2019 Oct; 62(10):1928-1937. PubMed ID: 31414143
[TBL] [Abstract][Full Text] [Related]
32. The expanding incretin universe: from basic biology to clinical translation.
Drucker DJ; Holst JJ
Diabetologia; 2023 Oct; 66(10):1765-1779. PubMed ID: 36976349
[TBL] [Abstract][Full Text] [Related]
33. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
34. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
35. Chronic exposure to incretin metabolites GLP-1(9-36) and GIP(3-42) affect islet morphology and beta cell health in high fat fed mice.
Sridhar A; Khan D; Babu G; Irwin N; Gault VA; Flatt PR; Moffett CR
Peptides; 2024 Aug; 178():171254. PubMed ID: 38815655
[TBL] [Abstract][Full Text] [Related]
36. Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?
Yabe D; Seino Y; Seino Y
J Diabetes Investig; 2018 Jan; 9(1):21-24. PubMed ID: 28746743
[TBL] [Abstract][Full Text] [Related]
37. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
38. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
40. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]